Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Other Non-Current Liabilities (2016 - 2025)

IGC Pharma (IGC) has disclosed Other Non-Current Liabilities for 14 consecutive years, with $16000.0 as the latest value for Q1 2025.

  • Quarterly Other Non-Current Liabilities fell 20.0% to $16000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $16000.0 through Mar 2025, down 20.0% year-over-year, with the annual reading at $16000.0 for FY2025, 20.0% down from the prior year.
  • Other Non-Current Liabilities for Q1 2025 was $16000.0 at IGC Pharma, roughly flat from $16000.0 in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $21000.0 in Q1 2023, with the low at $15000.0 in Q1 2021.
  • Average Other Non-Current Liabilities over 5 years is $17058.8, with a median of $16000.0 recorded in 2022.
  • The sharpest move saw Other Non-Current Liabilities skyrocketed 31.25% in 2023, then decreased 20.0% in 2025.
  • Over 5 years, Other Non-Current Liabilities stood at $15000.0 in 2021, then changed by 0.0% to $15000.0 in 2022, then grew by 13.33% to $17000.0 in 2023, then dropped by 5.88% to $16000.0 in 2024, then changed by 0.0% to $16000.0 in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $16000.0, $16000.0, and $20000.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.